Literature DB >> 30005311

Socio-cognitive functioning in stimulant polysubstance users.

Sara L Kroll1, Michael D Wunderli1, Matthias Vonmoos1, Lea M Hulka1, Katrin H Preller1, Oliver G Bosch1, Markus R Baumgartner2, Boris B Quednow3.   

Abstract

BACKGROUND: Using more than one psychotropic substance is accompanied by increased risks for psychiatric and physical disorders. Accordingly, deficits in basal cognitive functions have been consistently associated with polysubstance use (PSU), whereas little is known about potential impairments in more complex socio-cognitive skills, which are relevant for daily-life functioning. Therefore, we investigated the effects of toxicological validated stimulant PSU on social cognition under consideration of potential cumulative effects.
METHODS: We compared socio-cognitive performances of 47 individuals with stimulant PSU with 59 matched stimulant-naïve controls using the Multifaceted Empathy Test (MET) and the Movie for the Assessment of Social Cognition (MASC). Additionally, social network size was assessed by the Social Network Questionnaire (SNQ). Hair and urine testing was employed to categorize three PSU subgroups (3, 4, and ≥5 substances used) and to ensure drug abstinence in controls.
RESULTS: Individuals with stimulant PSU showed lower emotional empathy (MET) and a smaller social network (SNQ) compared to controls (both with linear trends for increasing number of used substances: p < .05). In contrast, cognitive empathy (MET and MASC) was largely unaffected by PSU. Additional linear regression analyses within PSU individuals revealed number of used substances as the best predictor for inferior performance in emotional empathy (p < .01), while severity of the use of single substances or substance-classes did not show a significant impact.
CONCLUSION: These findings demonstrate cumulative adverse effects of stimulant PSU on an important facet of socio-cognitive functioning. Therefore, emotional empathy deficits should be targeted in future interventions and rehabilitations for individuals with PSU.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Emotion perception; Emotion recognition; Empathy; Poly drug use; Stimulants; Theory-of-Mind

Mesh:

Substances:

Year:  2018        PMID: 30005311     DOI: 10.1016/j.drugalcdep.2018.06.001

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  6 in total

1.  Impaired empathy and increased anger following social exclusion in non-intoxicated opioid users.

Authors:  Molly Carlyle; Megan Rowley; Tobias Stevens; Anke Karl; Celia J A Morgan
Journal:  Psychopharmacology (Berl)       Date:  2019-11-05       Impact factor: 4.530

2.  Polysubstance Use in Early Adulthood: Patterns and Developmental Precursors in an Urban Cohort.

Authors:  Annekatrin Steinhoff; Laura Bechtiger; Denis Ribeaud; Manuel P Eisner; Boris B Quednow; Lilly Shanahan
Journal:  Front Behav Neurosci       Date:  2022-01-27       Impact factor: 3.558

3.  Editorial: Polysubstance Abuse and Cognitive Dysfunction.

Authors:  Bruno Kluwe-Schiavon; Thiago Wendt Viola; Rodrigo Grassi-Oliveira; Saulo Gantes Tractenberg
Journal:  Front Behav Neurosci       Date:  2022-07-26       Impact factor: 3.617

4.  Decoding Emotion in Drug Abusers: Evidence for Face and Body Emotion Recognition and for Disgust Emotion.

Authors:  Natale Salvatore Bonfiglio; Roberta Renati; Gabriella Bottini
Journal:  Eur J Investig Health Psychol Educ       Date:  2022-09-17

5.  DRD4, DRD2, DAT1, and ANKK1 Genes Polymorphisms in Patients with Dual Diagnosis of Polysubstance Addictions.

Authors:  Jolanta Masiak; Jolanta Chmielowiec; Krzysztof Chmielowiec; Anna Grzywacz
Journal:  J Clin Med       Date:  2020-11-08       Impact factor: 4.241

6.  Psychotically driven aggression is associated with greater mentalizing challenges in psychotic spectrum disorders.

Authors:  Anette Gm Johansson; Malin Källman; Lennart Högman; Marianne Kristiansson; Håkan Fischer; Sven Bölte
Journal:  BMC Psychiatry       Date:  2020-09-29       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.